Sutro Biopharma, Inc. (STRO) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 16 Buy, 2 Hold, 1 Sell.
The consensus price target is $9.86 (low: $2.00, high: $15.00), representing a downside of 66.9% from the current price $29.77.
Analysts estimate Earnings Per Share (EPS) of $-28.98 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.96 vs est $-28.98 (beat +89.8%). 2025: actual $-22.49 vs est $-17.81 (missed -26.3%). Analyst accuracy: 0%.
STRO Stock — 12-Month Price Forecast
$9.86
▼ -66.88% Downside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Sutro Biopharma, Inc., the average price target is $9.86, with a high forecast of $15.00, and a low forecast of $2.00.
The average price target represents a -66.88% change from the last price of $29.77.
Highest Price Target
$15.00
Average Price Target
$9.86
Lowest Price Target
$2.00
STRO Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Sutro Biopharma, Inc. in the past 3 months
EPS Estimates — STRO
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.96
vs Est –$28.98
▲ 879.1% off
2025
Actual –$22.49
vs Est –$17.81
▼ 20.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — STRO
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.062B
vs Est $0.059B
▲ 4.8% off
2025
Actual $0.102B
vs Est $0.099B
▲ 3.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
